JPWO2020118252A5 - - Google Patents

Info

Publication number

JPWO2020118252A5

JPWO2020118252A5 JP2021531722A JP2021531722A JPWO2020118252A5 JP WO2020118252 A5 JPWO2020118252 A5 JP WO2020118252A5 JP 2021531722 A JP2021531722 A JP 2021531722A JP 2021531722 A JP2021531722 A JP 2021531722A JP WO2020118252 A5 JPWO2020118252 A5 JP WO2020118252A5

Authority

JP

Japan

Prior art keywords

composition

prostate cancer

subject

item

administered

Prior art date

2022-11-29

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 claims description 41
• 206010060862 Prostate cancer Diseases 0.000 claims description 30
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 30
• 239000000203 mixture Substances 0.000 claims description 26
• 230000002401 inhibitory effect Effects 0.000 claims description 14
• 238000011282 treatment Methods 0.000 claims description 14
• 108010080146 androgen receptors Proteins 0.000 claims description 12
• 239000003112 inhibitor Substances 0.000 claims description 11
• 238000000634 powder X-ray diffraction Methods 0.000 claims description 11
• 238000002560 therapeutic procedure Methods 0.000 claims description 9
• 230000011664 signaling Effects 0.000 claims description 8
• GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 claims description 4
• 229960000853 abiraterone Drugs 0.000 claims description 4
• WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical group C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 claims description 4
• 229960004671 enzalutamide Drugs 0.000 claims description 4
• 230000001394 metastastic effect Effects 0.000 claims description 4
• 206010061289 metastatic neoplasm Diseases 0.000 claims description 4
• 229940123237 Taxane Drugs 0.000 claims description 3
• HJBWBFZLDZWPHF-UHFFFAOYSA-N apalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S HJBWBFZLDZWPHF-UHFFFAOYSA-N 0.000 claims description 3
• 229950007511 apalutamide Drugs 0.000 claims description 3
• DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 3
• 102000001307 androgen receptors Human genes 0.000 claims 3
• 238000000034 method Methods 0.000 description 80
• 150000003839 salts Chemical class 0.000 description 34
• 102100032187 Androgen receptor Human genes 0.000 description 9
• 239000003814 drug Substances 0.000 description 8
• 229940124597 therapeutic agent Drugs 0.000 description 8
• 102000007066 Prostate-Specific Antigen Human genes 0.000 description 7
• 108010072866 Prostate-Specific Antigen Proteins 0.000 description 7
• 238000009093 first-line therapy Methods 0.000 description 3
• 238000009167 androgen deprivation therapy Methods 0.000 description 2
• 210000001519 tissue Anatomy 0.000 description 2
• 108091005625 BRD4 Proteins 0.000 description 1
• 102100029895 Bromodomain-containing protein 4 Human genes 0.000 description 1
• 102000011787 Histone Methyltransferases Human genes 0.000 description 1
• 108010036115 Histone Methyltransferases Proteins 0.000 description 1
• 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 1
• 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
• 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
• 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
• 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
• 238000011374 additional therapy Methods 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 229960003668 docetaxel Drugs 0.000 description 1
• 230000000683 nonmetastatic effect Effects 0.000 description 1
• 238000011474 orchiectomy Methods 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 238000009094 second-line therapy Methods 0.000 description 1
• 238000002604 ultrasonography Methods 0.000 description 1
• LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 description 1
• 229960001183 venetoclax Drugs 0.000 description 1